New stroke drug in trialsBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7290.818/a (Published 07 April 2001) Cite this as: BMJ 2001;322:818
- Abi Berger
A new drug that limits brain damage after a stroke has entered large scale (phase III) clinical trials which, if successful, could lead to its being licensed. The drug, made by Bristol-Myers Squibb in the United States, has been designed to prevent the cell death that tends to follow an ischaemic episode (Nature Medicine 2001;7:471-7).
Soon after an ischaemic stroke occurs, the core area of the brain immediately around the occluded blood vessel loses most of its oxygen supply and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial